{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:18:11Z","timestamp":1788013091546,"version":"build-2784847793"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dasatinib, a second-generation tyrosine kinase inhibitor widely used for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL), has been reported in association with rare cases of chylothorax.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically summarize published case reports and complement these findings with pharmacovigilance data in order to characterize the clinical presentation, management, and outcomes of dasatinib-associated chylothorax.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted in accordance with PRISMA 2020 recommendations. PubMed\/MEDLINE and an institutional discovery platform were searched for case reports and case series published up to February 13, 2026. Eligible reports included patients developing chylothorax during dasatinib therapy. In parallel, data from the FDA Adverse Event Reporting System (FAERS) were analyzed through September 30, 2024. Descriptive analyses were performed. FAERS data were interpreted as hypothesis-generating only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-two publications describing 44 patients met the inclusion criteria. Patients ranged from 5 to 90\u00a0years of age, with a slight male predominance. Time from dasatinib initiation to chylothorax onset varied from 2\u00a0months to 10\u00a0years. Management most commonly involved drug discontinuation and thoracentesis, frequently followed by clinical resolution. FAERS analysis identified 104 unique reports of chylothorax associated with dasatinib, all classified as serious adverse events; severe outcomes were uncommon. Reporting trends increased over time, particularly between 2017 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>Evidence derives from case reports and spontaneous reporting data, which do not allow estimation of incidence or causal inference and are subject to reporting bias and incomplete information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dasatinib-associated chylothorax is an uncommon but clinically relevant event that may occur even after prolonged therapy. Long-term monitoring and prompt recognition are essential. Findings from pharmacovigilance data should be interpreted cautiously and considered hypothesis-generating. Further studies using large retrospective administrative databases are warranted to formally evaluate this potential association.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43441-026-00966-4","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:12:39Z","timestamp":1778519559000},"page":"1198-1209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9092-6588","authenticated-orcid":false,"given":"Eleonora","family":"Castellana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8271-1991","authenticated-orcid":false,"given":"Patricia Madalina","family":"Budau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Miglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-4161","authenticated-orcid":false,"given":"Paola","family":"Milla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rachele","family":"Chiappetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"40","key":"966_CR1","first-page":"74","volume":"1","author":"Y Alqattan","year":"2022","unstructured":"Alqattan Y, Ali S, Almohammad R, Kayali N, Alhuraiji A. Dasatinib-induced chylothorax in chronic myeloid leukemia. Gulf J Oncol. 2022;1(40):74\u20137.","journal-title":"Gulf J Oncol"},{"issue":"1","key":"966_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.24018\/ejmed.2024.6.1.2022","volume":"6","author":"B Shaw","year":"2024","unstructured":"Shaw B, Mubarak N, Nuaimi M, Persall C, Vollenweider T, Shaw R, et al. A rare case of recurrent dasatinib-induced chylothorax years after initial treatment. Eur J Med Health Sci. 2024;6(1):7\u201310. https:\/\/doi.org\/10.24018\/ejmed.2024.6.1.2022.","journal-title":"Eur J Med Health Sci"},{"issue":"3","key":"966_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/jha2.226","volume":"2","author":"T Paul","year":"2021","unstructured":"Paul T, Ellahie AY, Almohtasib YS, Sinha U, El Omri H. Dasatinib-induced chylothorax: an unusual presentation of a common adverse event\u2014a case report with literature review. EJHaem. 2021;2(3):545\u201350. https:\/\/doi.org\/10.1002\/jha2.226.","journal-title":"EJHaem"},{"issue":"21","key":"966_CR4","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.2169\/internalmedicine.3002-19","volume":"58","author":"H Sasaki","year":"2019","unstructured":"Sasaki H, Kimizuka Y, Ogata H, Okada Y, Ota S, Sano T, et al. Successful control of dasatinib-related chylothorax by the Japanese herbal medicine \u201cGoreisan.\u201d Intern Med. 2019;58(21):3139\u201341. https:\/\/doi.org\/10.2169\/internalmedicine.3002-19.","journal-title":"Intern Med"},{"issue":"10","key":"966_CR5","doi-asserted-by":"publisher","first-page":"003601","DOI":"10.12890\/2022_003601","volume":"9","author":"N Bradt","year":"2022","unstructured":"Bradt N, Olbrechts F, Alexander P, Salembier A. A dasatinib-induced chylothorax persisting after the discontinuation of dasatinib. Eur J Case Rep Intern Med. 2022;9(10):003601. https:\/\/doi.org\/10.12890\/2022_003601.","journal-title":"Eur J Case Rep Intern Med"},{"issue":"4","key":"966_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4103\/1817-1737.191871","volume":"11","author":"L Ferreiro","year":"2016","unstructured":"Ferreiro L, San-Jos\u00e9 E, Su\u00e1rez-Antelo J, Vald\u00e9s L. Dasatinib-induced pleural effusion: chylothorax, an option to consider. Ann Thorac Med. 2016;11(4):289\u201393. https:\/\/doi.org\/10.4103\/1817-1737.191871.","journal-title":"Ann Thorac Med"},{"issue":"25","key":"966_CR7","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908\u201314. https:\/\/doi.org\/10.1200\/JCO.2007.12.0329.","journal-title":"J Clin Oncol"},{"key":"966_CR8","doi-asserted-by":"publisher","first-page":"e938319","DOI":"10.12659\/AJCR.938319","volume":"23","author":"RL Kelly","year":"2022","unstructured":"Kelly RL, Bae JY, D\u2019Annunzio S, Montanari F. Diagnostic pitfalls of chylothorax after dasatinib treatment of chronic myeloid leukemia. Am J Case Rep. 2022;23:e938319. https:\/\/doi.org\/10.12659\/AJCR.938319.","journal-title":"Am J Case Rep"},{"issue":"1","key":"966_CR9","first-page":"76","volume":"34","author":"RJG Mart\u00ednez","year":"2023","unstructured":"Mart\u00ednez RJG, Gea CS, Martin-Riera V, Ruiz ARG, Barzanti RP, Ferrer-Costa R, et al. Dasatinib-induced chylothorax: a clinical laboratory\u2019s perspective. EJIFCC. 2023;34(1):76\u201380.","journal-title":"EJIFCC"},{"issue":"7","key":"966_CR10","doi-asserted-by":"publisher","first-page":"003921","DOI":"10.12890\/2023_003921","volume":"10","author":"A Garcia-Zamalloa","year":"2023","unstructured":"Garcia-Zamalloa A, Basauri B, Urcelay G, Sainz A. Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit? Eur J Case Rep Intern Med. 2023;10(7):003921. https:\/\/doi.org\/10.12890\/2023_003921.","journal-title":"Eur J Case Rep Intern Med"},{"issue":"1","key":"966_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/CPM.0000000000000018","volume":"21","author":"J Nestor","year":"2014","unstructured":"Nestor J, Jennings MD, Huggins T, Kummerfeldt C, Wisniewski C, Davis J, et al. Dasatinib-induced chylous pleural effusions. Clin Pulm Med. 2014;21(1):42\u20135. https:\/\/doi.org\/10.1097\/CPM.0000000000000018.","journal-title":"Clin Pulm Med"},{"issue":"4","key":"966_CR12","doi-asserted-by":"publisher","first-page":"512A","DOI":"10.1378\/chest.1388575","volume":"142","author":"H Inaty","year":"2012","unstructured":"Inaty H, Tabba MK. A rare case of chylothorax attributed to metastatic prostate carcinoma. Chest. 2012;142(4):512A.","journal-title":"Chest"},{"issue":"4","key":"966_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.13175\/swjpccs036-22","volume":"25","author":"M Mohammed","year":"2022","unstructured":"Mohammed M, Abdelrahim M, Sharma K. Medical image of the month: infected dasatinib induced chylothorax\u2014the first reported case. Southwest J Pulm Crit Care Sleep. 2022;25(4):47\u20139. https:\/\/doi.org\/10.13175\/swjpccs036-22.","journal-title":"Southwest J Pulm Crit Care Sleep"},{"key":"966_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2022.101662","author":"G Makimoto","year":"2022","unstructured":"Makimoto G, Misawa M, Maeda Y, Kiura K. Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia. Respir Med Case Rep. 2022. https:\/\/doi.org\/10.1016\/j.rmcr.2022.101662.","journal-title":"Respir Med Case Rep"},{"key":"966_CR15","unstructured":"PRISMA. Transparent reporting of systematic reviews and meta-analyses. Accessed 20 Nov 2023. http:\/\/www.prisma-statement.org\/?AspxAutoDetectCookieSupport=1."},{"key":"966_CR16","unstructured":"WorldCat Discovery \u2013 University of Turin. Turin: University of Turin; [cited 2025 Jun 25]. Available from: https:\/\/unito.on.worldcat.org\/discovery."},{"key":"966_CR17","unstructured":"FDA Adverse Event Reporting System (FAERS) public dashboard. Accessed Jan 2025. https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee."},{"issue":"15","key":"966_CR18","doi-asserted-by":"publisher","first-page":"1414268","DOI":"10.3389\/fphar.2024.1414268","volume":"3","author":"K Niu","year":"2024","unstructured":"Niu K, Fan M, Gao W, Chen C, Dai G. Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system. Front Pharmacol. 2024;3(15):1414268. https:\/\/doi.org\/10.3389\/fphar.2024.1414268.","journal-title":"Front Pharmacol"},{"issue":"1","key":"966_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4274\/tjh.2012.0196","volume":"32","author":"YM Huang","year":"2015","unstructured":"Huang YM, Wang CH, Huang JS, Yeh KY, Lai CH, Wu TH, et al. Dasatinib-related chylothorax. Turk J Haematol. 2015;32(1):68\u201372. https:\/\/doi.org\/10.4274\/tjh.2012.0196.","journal-title":"Turk J Haematol"},{"key":"966_CR20","doi-asserted-by":"publisher","unstructured":"Baloch ZQ, Abbas SA, Bhatti H, Braver Y, Ali SK. Dasatinib-induced chylothorax in chronic myeloid leukemia. In: Baylor University Medical Center proceedings, vol. 30. Taylor & Francis; 2017. pp. 71\u201373. https:\/\/doi.org\/10.1080\/08998280.2017.11929535.","DOI":"10.1080\/08998280.2017.11929535"},{"issue":"12","key":"966_CR21","doi-asserted-by":"publisher","first-page":"e231653","DOI":"10.1136\/bcr-2019-231653","volume":"12","author":"A Al-Abcha","year":"2019","unstructured":"Al-Abcha A, Iftikhar MH, Abu Rous F, Laird-Fick H. Chylothorax: complication attributed to dasatinib use. BMJ Case Rep. 2019;12(12):e231653. https:\/\/doi.org\/10.1136\/bcr-2019-231653.","journal-title":"BMJ Case Rep"},{"issue":"5","key":"966_CR22","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10637-020-00932-3","volume":"38","author":"B Chen","year":"2020","unstructured":"Chen B, Wu Z, Wang Q, Li W, Cheng D. Dasatinib-induced chylothorax: report of a case and review of the literature. Invest New Drugs. 2020;38(5):1627\u201332. https:\/\/doi.org\/10.1007\/s10637-020-00932-3.","journal-title":"Invest New Drugs"},{"issue":"7","key":"966_CR23","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1097\/MPH.0000000000001619","volume":"42","author":"K Hickman","year":"2020","unstructured":"Hickman K, Diaz E, Graham R, Adams R, Ngwube A. Dasatinib-induced chylothorax in chronic myelogenous leukemia in pediatric patient: report of a case and review of literature. J Pediatr Hematol Oncol. 2020;42(7):e665\u20137. https:\/\/doi.org\/10.1097\/MPH.0000000000001619.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"966_CR24","doi-asserted-by":"publisher","first-page":"e00753","DOI":"10.1002\/rcr2.753","volume":"9","author":"CC Hsu","year":"2021","unstructured":"Hsu CC, Hsu JF, Wu KL. Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review. Respirol Case Rep. 2021;9(6):e00753. https:\/\/doi.org\/10.1002\/rcr2.753.","journal-title":"Respirol Case Rep"},{"issue":"1","key":"966_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/14782715241237577","volume":"54","author":"IK Ng","year":"2024","unstructured":"Ng IK, Ruparel M, Chan EH, Khoo KL. Drug-induced chylothorax as a rare pleural complication in dasatinib therapy for chronic myeloid leukaemia. J R Coll Physicians Edinb. 2024;54(1):44\u20137. https:\/\/doi.org\/10.1177\/14782715241237577.","journal-title":"J R Coll Physicians Edinb"},{"issue":"9","key":"966_CR26","doi-asserted-by":"publisher","first-page":"e68479","DOI":"10.7759\/cureus.68479","volume":"16","author":"CE McGonegal","year":"2024","unstructured":"McGonegal CE, Baskar S. Dasatinib-induced bilateral chylothorax: a case report. Cureus. 2024;16(9):e68479. https:\/\/doi.org\/10.7759\/cureus.68479.","journal-title":"Cureus"},{"issue":"1","key":"966_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.21037\/tcr-22-1983","volume":"12","author":"Q Liu","year":"2023","unstructured":"Liu Q, Fu J, Zhang A. Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review. Transl Cancer Res. 2023;12(1):194\u2013200. https:\/\/doi.org\/10.21037\/tcr-22-1983.","journal-title":"Transl Cancer Res"},{"issue":"4S","key":"966_CR28","doi-asserted-by":"publisher","first-page":"A612","DOI":"10.1016\/j.chest.2023.07.2350","volume":"164","author":"J Anwar","year":"2023","unstructured":"Anwar J, Vikash S, Asghar Z, Bogart M, Astua AJ. A rare case of Dasatinib-induced chylothorax. Chest. 2023;164(4S):A612. https:\/\/doi.org\/10.1016\/j.chest.2023.07.2350.","journal-title":"Chest"},{"key":"966_CR29","first-page":"A6712","volume":"201","author":"M Bogart","year":"2020","unstructured":"Bogart M, Amoun T, Messano L, Dacey J, Markley DJ. A rare case of chylothorax secondary to dasatinib. Am J Respir Crit Care Med. 2020;201:A6712.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4S","key":"966_CR30","doi-asserted-by":"publisher","first-page":"A1706","DOI":"10.1016\/j.chest.2021.07.1552","volume":"160","author":"JL Castellanos","year":"2021","unstructured":"Castellanos JL, Rios G, Aguilar J, Cifuentes J, De Ajanel MEC, Castillo JW. Chylotorax: secondary complication to the use of dasatinib. Chest. 2021;160(4S):A1706. https:\/\/doi.org\/10.1016\/j.chest.2021.07.1552.","journal-title":"Chest"},{"issue":"4S","key":"966_CR31","doi-asserted-by":"publisher","first-page":"A571","DOI":"10.1016\/j.chest.2016.08.660","volume":"150","author":"A Chua","year":"2016","unstructured":"Chua A, Cleven K, Appel D. Chylothorax and PAH after treatment with Dasatinib: a case report. Chest. 2016;150(4S):A571. https:\/\/doi.org\/10.1016\/j.chest.2016.08.660.","journal-title":"Chest"},{"issue":"4S","key":"966_CR32","doi-asserted-by":"publisher","first-page":"A426","DOI":"10.1016\/j.chest.2022.08.1200","volume":"162","author":"R Dalbah","year":"2022","unstructured":"Dalbah R, Alkharabsheh M, Al-Khateeb M, Fahmawi SS. Recurrent dasatinib-induced chylothorax. Chest. 2022;162(4S):A426. https:\/\/doi.org\/10.1016\/j.chest.2022.08.1200.","journal-title":"Chest"},{"issue":"4S","key":"966_CR33","doi-asserted-by":"publisher","first-page":"A08","DOI":"10.1016\/j.chest.2022.08.475","volume":"162","author":"C Espinosa","year":"2022","unstructured":"Espinosa C, Alvarez A, Ciment AJ. Dasatinib-induced chylothorax: a rare case report of a 50-year-old man with chronic myeloid leukemia. Chest. 2022;162(4S):A08. https:\/\/doi.org\/10.1016\/j.chest.2022.08.475.","journal-title":"Chest"},{"issue":"4S","key":"966_CR34","doi-asserted-by":"publisher","first-page":"A374","DOI":"10.1016\/j.chest.2019.08.1227","volume":"156","author":"S Grover","year":"2019","unstructured":"Grover S, Meenakshisundaram R, Dakshinesh P. A rare case of dasatinib-induced chylothorax. Chest. 2019;156(4S):A374. https:\/\/doi.org\/10.1016\/j.chest.2019.08.1227.","journal-title":"Chest"},{"issue":"4S","key":"966_CR35","doi-asserted-by":"publisher","first-page":"A1365","DOI":"10.1016\/j.chest.2021.07.1248","volume":"160","author":"C Haddad","year":"2021","unstructured":"Haddad C, Kewan T, Saleem T, Daw H. Bilateral chylothorax and anasarca caused by dasatinib in a patient with chronic myelogenous leukemia. Chest. 2021;160(4S):A1365. https:\/\/doi.org\/10.1016\/j.chest.2021.07.1248.","journal-title":"Chest"},{"issue":"4S","key":"966_CR36","doi-asserted-by":"publisher","first-page":"A579","DOI":"10.1016\/j.chest.2022.04.113","volume":"162","author":"V Jasti","year":"2022","unstructured":"Jasti V, Willett A, Anderson J. Dasatinib-induced chylothorax. Chest. 2022;162(4S):A579. https:\/\/doi.org\/10.1016\/j.chest.2022.04.113.","journal-title":"Chest"},{"issue":"4S","key":"966_CR37","doi-asserted-by":"publisher","first-page":"A744","DOI":"10.1016\/j.chest.2024.06.2244","volume":"166","author":"J Kaufman","year":"2024","unstructured":"Kaufman J, Macdissi T, Sorrell M, Ganesan P, Mukherjee S, Krajicek BJ. Chylothorax: a rare \u201cmurky\u201d complication of dasatinib. Chest. 2024;166(4S):A744. https:\/\/doi.org\/10.1016\/j.chest.2024.06.2244.","journal-title":"Chest"},{"issue":"8","key":"966_CR38","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s42399-020-00280-6","volume":"2","author":"SS Kho","year":"2020","unstructured":"Kho SS, Nyanti LE, Chai CS, Tie ST. Dasatinib as a probable cause of bilateral chylothorax in a patient with chronic myeloid leukemia: case report. SN Compr Clin Med. 2020;2(8):817\u201321. https:\/\/doi.org\/10.1007\/s42399-020-00280-6.","journal-title":"SN Compr Clin Med"},{"issue":"4S","key":"966_CR39","doi-asserted-by":"publisher","first-page":"A22","DOI":"10.1016\/j.chest.2018.08.829","volume":"154","author":"M Korotun","year":"2018","unstructured":"Korotun M, Agrawal A, Wang J. Chylothorax: a rare complication of dasatinib. Chest. 2018;154(4S):A22. https:\/\/doi.org\/10.1016\/j.chest.2018.08.829.","journal-title":"Chest"},{"issue":"10","key":"966_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.13175\/swjpcc097-18","volume":"25","author":"M Mohammed","year":"2022","unstructured":"Mohammed M, Abdelrahim M, Sharma K. Infected dasatinib-induced chylothorax\u2014the first reported case. Southwest J Pulm Crit Care Sleep. 2022;25(10):47\u20139. https:\/\/doi.org\/10.13175\/swjpcc097-18.","journal-title":"Southwest J Pulm Crit Care Sleep"},{"issue":"9","key":"966_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.arbr.2020.07.008","volume":"56","author":"V Molina","year":"2020","unstructured":"Molina V, Va\u00f1es S, Castell\u00f3 C, Chiner E. Chylothorax secondary to dasatinib. Arch Bronconeumol. 2020;56(9):599\u2013601. https:\/\/doi.org\/10.1016\/j.arbr.2020.07.008.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"966_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/2772-6355.309262","volume":"1","author":"M Natraj","year":"2018","unstructured":"Natraj M, Dhanasekar D, Ayub II, Arshad AM, Rajagopalan R, Chandrasekar T. A strange cause of chylothorax\u2014Dasatinib induced. J Assoc Pulmonol Tamil Nadu. 2018;1(1):33\u20135.","journal-title":"J Assoc Pulmonol Tamil Nadu"},{"issue":"2","key":"966_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1373\/clinchem.2014.234708","volume":"62","author":"JB Oudart","year":"2016","unstructured":"Oudart JB, Pax C, Bennani-Smires B, Ramont L. Milky pleural fluid. Clin Chem. 2016;62(2):315\u20139. https:\/\/doi.org\/10.1373\/clinchem.2014.234708.","journal-title":"Clin Chem"},{"key":"966_CR44","first-page":"A3479","volume":"195","author":"PC Trivedi","year":"2017","unstructured":"Trivedi PC, Hapangama S, Perez-Batista E, Iftikhar A, Gumpeni R, Smith A. Dasatinib induced chylothorax. Am J Respir Crit Care Med. 2017;195:A3479.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"966_CR45","first-page":"183","volume":"31","author":"I Tsiouprou","year":"2018","unstructured":"Tsiouprou I, Apostolidou E, Papakosta D, Zaharias A, Spyratos D, Porpodis K. Dasatinib-induced chylothorax in a patient with chronic myeloid leukemia: a case report. Pneumon. 2018;31(3):183\u20136.","journal-title":"Pneumon"},{"issue":"5","key":"966_CR46","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.7534\/j.issn.1009-2137.2016.05.012","volume":"24","author":"L Yang","year":"2016","unstructured":"Yang L, Lu N, Jing Y, Yu L. Chylothorax related with dasatinib in the treatment of chronic myeloid leukemia: report of 3 cases. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(5):1348\u201353. https:\/\/doi.org\/10.7534\/j.issn.1009-2137.2016.05.012.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"966_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.33590\/emjhematol\/10311304","volume":"7","author":"E Zengin","year":"2019","unstructured":"Zengin E, Sarper N, Aylan Gelen S, Top\u00e7u S. Resistant bilateral chylous effusion as a late adverse effect of dasatinib treatment in chronic myeloid leukaemia. EMJ Hematol. 2019;7(1):93\u20137.","journal-title":"EMJ Hematol"},{"issue":"4","key":"966_CR48","doi-asserted-by":"publisher","first-page":"A4409","DOI":"10.1016\/j.chest.2025.07.2460","volume":"168","author":"N Thakur","year":"2025","unstructured":"Thakur N, Gouda D, Avuthu S. Dasatinib-related chylothorax: a rare case with persistent pleural fluid reaccumulation. Chest. 2025;168(4):A4409\u201310. https:\/\/doi.org\/10.1016\/j.chest.2025.07.2460.","journal-title":"Chest"},{"issue":"4","key":"966_CR49","doi-asserted-by":"publisher","first-page":"A4389","DOI":"10.1016\/j.chest.2025.07.2449","volume":"168","author":"Z Naseer","year":"2025","unstructured":"Naseer Z, Tran A, Rehm J, Ahmed S. Chyl-lateral damage: dasatinib-induced loculated chylothorax. Chest. 2025;168(4):A4389. https:\/\/doi.org\/10.1016\/j.chest.2025.07.2449.","journal-title":"Chest"},{"issue":"4","key":"966_CR50","doi-asserted-by":"publisher","first-page":"A4355","DOI":"10.1016\/j.chest.2025.07.2431","volume":"168","author":"Z Brodie","year":"2025","unstructured":"Brodie Z, Wichman TO. Double trouble: a case of dasatinib-induced pulmonary arterial hypertension and recurrent chylothorax. Chest. 2025;168(4):A4355\u20136. https:\/\/doi.org\/10.1016\/j.chest.2025.07.2431.","journal-title":"Chest"},{"issue":"5","key":"966_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/ot9.0000000000000114","volume":"11","author":"RI Thaker","year":"2025","unstructured":"Thaker RI, Gor A. Chylothorax and 10-year chronicity after Sprycel (dasatinib) treatment for chronic myelogenous leukemia: a case report and review. Oncol Transl Med. 2025;11(5):251\u20133. https:\/\/doi.org\/10.1097\/ot9.0000000000000114.","journal-title":"Oncol Transl Med"},{"issue":"3","key":"966_CR52","doi-asserted-by":"publisher","first-page":"e41328","DOI":"10.1097\/MD.0000000000000041328","volume":"104","author":"T-W Pai","year":"2025","unstructured":"Pai T-W, Huang C-W. Low-dose dasatinib-induced chylothorax, pulmonary hypertension, and pericardial effusion in a patient with chronic myeloid leukemia: a case report and literature review. Medicine. 2025;104(3):e41328. https:\/\/doi.org\/10.1097\/MD.0000000000000041328.","journal-title":"Medicine"},{"issue":"1","key":"966_CR53","doi-asserted-by":"publisher","first-page":"e27503","DOI":"10.1002\/ppul.27503","volume":"60","author":"LYJ Wee","year":"2025","unstructured":"Wee LYJ, Lam JCM, Teoh OH. Dasatinib-induced chylothorax treated with diuretics and steroids. Pediatr Pulmonol. 2025;60(1):e27503. https:\/\/doi.org\/10.1002\/ppul.27503.","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"966_CR54","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.21037\/jtd-23-1636","volume":"16","author":"M Bhatnagar","year":"2024","unstructured":"Bhatnagar M, Fisher A, Ramsaroop S, Carter A, Pippard B. Chylothorax: pathophysiology, diagnosis, and management-a comprehensive review. J Thorac Dis. 2024;16(2):1645\u201361. https:\/\/doi.org\/10.21037\/jtd-23-1636.","journal-title":"J Thorac Dis"},{"issue":"5","key":"966_CR55","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3109\/10428194.2015.1122779","volume":"57","author":"LP Akard","year":"2016","unstructured":"Akard LP, Bixby D. Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase. Leuk Lymphoma. 2016;57(5):1002\u201314. https:\/\/doi.org\/10.3109\/10428194.2015.1122779.","journal-title":"Leuk Lymphoma"},{"key":"966_CR56","doi-asserted-by":"publisher","DOI":"10.1177\/00185787251337610","author":"E Castellana","year":"2025","unstructured":"Castellana E, Budau PM, Chiappetta MR. Pharmacovigilance and Stevens-Johnson syndrome\/toxic epidermal necrolysis: 55 years of retrospective analysis of the FDA adverse event reporting system (FAERS) database. Hosp Pharm. 2025. https:\/\/doi.org\/10.1177\/00185787251337610.","journal-title":"Hosp Pharm"},{"issue":"6","key":"966_CR57","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.clml.2017.02.023","volume":"17","author":"H Itamura","year":"2017","unstructured":"Itamura H, Kubota Y, Shindo T, Ando T, Kojima K, Kimura S. Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Clin Lymphoma Myeloma Leuk. 2017;17(6):370\u20134. https:\/\/doi.org\/10.1016\/j.clml.2017.02.023.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"33","key":"966_CR58","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.2174\/0113816128309071240626114308","volume":"30","author":"D Katsarou","year":"2024","unstructured":"Katsarou D, Kotanidou EP, Tsinopoulou VR, Tragiannidis A, Hatzipantelis E, Galli-Tsinopoulou A. Impact of tyrosine kinase inhibitors (TKIs) on growth in children and adolescents with chronic myeloid leukemia: a systematic review. Curr Pharm Des. 2024;30(33):2631\u201342. https:\/\/doi.org\/10.2174\/0113816128309071240626114308.","journal-title":"Curr Pharm Des"},{"key":"966_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/00185787251337618","volume":"60","author":"E Castellana","year":"2025","unstructured":"Castellana E, Budau PM, Chiappetta MR. Women and hyponatremia: an analysis of sex differences in adverse drug reactions. Hosp Pharm. 2025;60:309\u201313. https:\/\/doi.org\/10.1177\/00185787251337618.","journal-title":"Hosp Pharm"},{"issue":"1","key":"966_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2009.08.010","volume":"104","author":"EE McGrath","year":"2010","unstructured":"McGrath EE, Blades Z, Anderson PB. Chylothorax: aetiology, diagnosis and therapeutic options. Respir Med. 2010;104(1):1\u20138. https:\/\/doi.org\/10.1016\/j.rmed.2009.08.010.","journal-title":"Respir Med"},{"issue":"2","key":"966_CR61","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ejcts.2007.04.024","volume":"32","author":"SK Nair","year":"2007","unstructured":"Nair SK, Petko M, Hayward MP. Aetiology and management of chylothorax in adults. Eur J Cardiothorac Surg. 2007;32(2):362\u20139. https:\/\/doi.org\/10.1016\/j.ejcts.2007.04.024.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"966_CR62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12032-025-02620-9","volume":"42","author":"L Duranti","year":"2025","unstructured":"Duranti L, Tavecchio L, Rolli L, Uslenghi C, Solli P. Chylothorax in thoracic oncology: diagnostic challenges and management strategies. Med Oncol. 2025;42(3):70. https:\/\/doi.org\/10.1007\/s12032-025-02620-9.","journal-title":"Med Oncol"},{"key":"966_CR63","doi-asserted-by":"publisher","first-page":"1665484","DOI":"10.3389\/fphar.2025.1665484","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, Huang Y, Guo J, Liu X, Hu Y. Clinical characteristics and management of dasatinib-induced chylothorax: retrospective analysis based on case reports. Front Pharmacol. 2025;16:1665484. https:\/\/doi.org\/10.3389\/fphar.2025.1665484.","journal-title":"Front Pharmacol"}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00966-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:47:15Z","timestamp":1788011235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00966-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00966-4","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants consented to the publication of the research data.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}